Intermediate protocol After establishing tolerance with a beginner protocol, researchers may move to standard dosing
Activating sirtuins through adequate NAD+ levels is associated with improved mitochondrial function, reduced inflammation, and extended cellular lifespan
Experimental Setup Mice were implanted with pancreatic tumor cells and split into four treatment groups: Vehicle control (no treatment) Low-dose Reta (1 nmol/kg, subcutaneously) Anti-PD-1 immunotherapy (10 mg/kg, intraperitoneally) Combination Reta + anti-PD-1 Treatments were given once every three days for two weeks after tumors were established
Higher isn't necessarily better
Augmenting brain B 12 with fingolimod or potentially related molecules could enhance both current and future MS therapies. In their paper, the team at Sanford Burnham Prebys, with collaborators at University of Southern California, Juntendo University in Japan, Tokyo University of Pharmacy and Life Sciences and State University of New York, focused on the molecular functioning of FTY720 or fingolimod (Gilenya), a sphingosine 1-phosphate (S1P) receptor modulator that suppresses distribution of T and B immune cells errantly attacking the brains of MS patients
